The content that appears on this page is presented as an overview vs. comparative marketing. The provided information includes product information, overviews, buying guides, and product specifications. All trademarks, registered trademarks and service-marks mentioned on this site are the property of their respective owners. If something is factually inaccurate please contact us and let us know. By contributing your product facts helps to better serve our readers and the accuracy of the content.
The table below does not include all companies or all available products in the market but those that we promote as their affiliates. In full compliance with the FTC guidelines, please assume that any and all links on the table are affiliate links, and we may receive compensation if you click one of these and make a purchase. We are independently owned and the opinions expressed here are our own. All editorial content is written without prejudice or bias, regardless of sponsor or affiliate associations.
Colorectal Cancer is cancer of the colon or bowel wherein there’s an abnormal growth of cells in the rectum and colon. According to Robert J Fingerote, MD, MSc, BSc, the abnormal growth and multiplication of cancer cells is not limited only to the colon and rectum area. It can also affect other adjacent organs such as bones, the brain and the lungs.
Colorectal Cancer is often incurred due to genetics. If one member of the family has developed colorectal cancer in his lifetime, other members may get more prone to the disease. The possibility rises as a person reaches the age 45.
Colorectal Cancer Statistics
According to the National Cancer Institute, roughly 4.96% of the individuals may incur colorectal cancer in his or her lifetime. This means 1 out of 20 people are possibly at risk with this kind of disease.
This figure continues to rise as 143, 460 individuals are estimated to be suffering from colorectal cancer and more than 50,000 of them may die this year. Furthermore, when a patient approaches the age 74, the survival rate becomes dimmer. With this daunting statistics, it is no doubt colorectal cancer is a disease to be wary of.
Stivarga for Colorectal Cancer
With the aim of supporting colorectal cancer patients with their medication and treatment needs, a new drug was developed by Bayer Health Care Pharmaceuticals. Stivarga for colorectal cancer has been recently approved by the Food and Drug Administration of the US and can be used for patients with advanced colon cancer.
What Stivarga does is it suppresses the growth of enzymes that triggers growth of cancer cells through its multi-kinase inhibitor. Clinical studies of Stivarga for colorectal cancer show that Stivarga, along with best supportive care (BSC) live six months more compared to the five months for patients who were treated only with placebo and BSC.
According to FDA Press Announcement made by Director Richard Pazdur, M.D. of Office of Hematology and Oncology, Stivarga is the latest drug to demonstrate extension of cancer patients’ lives and next to Zaltrap, also the second drug approved by FDA for colorectal cancer within two months.
Breaking News for Stivarga
Together with the effectiveness, FDA approved Stivarga with a warning to the patients. Using Stivarga for colorectal cancer may come with the following side effects:
- Loss of appetite and subsequently, weight loss
- High blood pressure
- Some infections
- And changes in quality and volume of voice
Bayer Health Care Pharmaceuticals furthermore added that Stivarga costs $9,350 per month, but the company offered financial assistance to patients to help subsidize and afford the drug. Bayer is also happy to announce that their researches and efforts to help improve and cure people’s lives are paying off. Bayer is also doing further researches on Stivarga and how it might also help cure other types of cancer.